精密ゲノム検査市場- 世界の産業規模、シェア、動向、機会、予測、技術別、製品とサービス別（消耗品、機器、サービス）、用途別、最終用途別、地域別、競合別、2020～2030年

精密ゲノム検査の世界市場は、2024年に155億1,000万米ドルと評価され、2030年には209億8,000万米ドルに達すると予測され、予測期間中に5.12％の年間複合成長率（CAGR）で成長すると予測されています。

同市場は、ゲノムシーケンス技術の進歩、個別化医療の採用の増加、遺伝性疾患やがんの有病率の上昇により急速に拡大しています。精密ゲノム検査では、個人のDNAを解析することで、疾患の素因を評価し、治療方針を決定し、遺伝子プロファイルに基づいて医療介入をカスタマイズします。ヘルスケアシステムが世界的に精密医療へとシフトする中、ゲノム検査は最新の診断および治療法の基本要素になりつつあります。

次世代シーケンサー（NGS）は、ゲノム全体、エクソーム、または包括的な遺伝子解析のための標的遺伝子パネルの迅速なシーケンシングを可能にし、ゲノム検査のコスト削減と効率化に重要な役割を果たしています。これにより、がん診断、遺伝性疾患スクリーニング、薬理ゲノミクスなどの臨床応用において、ゲノム検査がより身近なものとなりました。さらに、Oxford NanoporeやPacBioのSMRTシーケンスのような第3世代シーケンシング（TGS）技術の開発により、DNA解析の精度と効率がさらに向上しています。

主な市場促進要因

遺伝性疾患とがんの有病率の増加

主な市場課題

高いコストと限られたアクセシビリティ

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の精密ゲノム検査市場に与える影響

第5章 世界の精密ゲノム検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別（次世代シーケンシング、ポリメラーゼ連鎖反応、マイクロアレイ技術、サンガーシーケンシング、CRISPR/Casシステム、その他）
  • 製品とサービス別（消耗品（キットと試薬）、機器、サービス）
  • 用途別（腫瘍学、心血管疾患、神経疾患、生殖保健、希少疾患、その他）
  • 最終用途別（病院・診療所、診断研究所、調査・学術機関、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の精密ゲノム検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の精密ゲノム検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の精密ゲノム検査市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の精密ゲノム検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの精密ゲノム検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 世界の精密ゲノム検査市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Danaher Corporation
• Merck KGaA
• Revvity, Inc.
• Maravai LifeSciences Holdings Inc.
• GenScript Biotech
• QIAGEN N.V.
• PacBio Biosciences Inc.
• Oxford Nanopore Technologies plc.
• Illumina, Inc.
• 10x Genomics, Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Precision Genomic Testing Market was valued at USD 15.51 billion in 2024 and is projected to reach USD 20.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.12% during the forecast period. The market is expanding rapidly due to advancements in genomic sequencing technologies, the increasing adoption of personalized medicine, and the rising prevalence of genetic disorders and cancers. Precision genomic testing involves analyzing an individual's DNA to assess disease predisposition, inform treatment decisions, and customize medical interventions based on genetic profiles. As healthcare systems globally shift toward precision medicine, genomic testing is becoming a fundamental component of modern diagnostics and therapeutics.

Next-generation sequencing (NGS) has played a key role in reducing the costs and enhancing the efficiency of genomic testing, enabling the rapid sequencing of entire genomes, exomes, or targeted gene panels for comprehensive genetic analysis. This has made genomic testing more accessible for clinical applications, such as cancer diagnostics, hereditary disease screening, and pharmacogenomics. Additionally, the development of third-generation sequencing (TGS) technologies, like Oxford Nanopore and PacBio's SMRT sequencing, has further improved the accuracy and efficiency of DNA analysis.

Key Market Drivers

Increasing Prevalence of Genetic Disorders and Cancer

The global precision genomic testing market is experiencing significant growth, driven by the increasing prevalence of genetic disorders and cancer worldwide. Precision genomic testing supports early detection, accurate diagnosis, and personalized treatment by analyzing an individual's genetic makeup. As demand for targeted therapies and precision medicine rises, the genomic testing market continues to expand, offering promising advancements in healthcare.

According to the CDC, when one parent carries an autosomal dominant disease, each child has a 50% chance of inheriting the associated genetic mutation. The rising prevalence of genetic disorders such as cystic fibrosis, sickle cell anemia, and Huntington's disease, largely due to greater awareness and improved diagnostic capabilities, is further driving market demand. Many inherited diseases require precise genetic analysis for proper diagnosis and management, making genomic testing a critical tool in modern medicine. Moreover, the growing use of whole genome sequencing and NGS technologies has enhanced the ability to identify genetic mutations linked to various hereditary conditions.

With approximately 10,000 distinct types of monogenic diseases-resulting from mutations in a single gene-that affect about 10 in every 1,000 people, the global prevalence of these diseases is estimated at 70 to 80 million individuals. Furthermore, cancer remains one of the leading causes of death worldwide, with millions of new cases diagnosed annually. Precision genomic testing plays a vital role in oncology by identifying genetic mutations that contribute to tumor formation.

Key Market Challenges

High Costs and Limited Accessibility

One of the primary challenges in the precision genomic testing market is the high cost associated with genomic sequencing and analysis. Advanced tests such as whole genome sequencing require sophisticated technologies, specialized expertise, and robust bioinformatics infrastructure, contributing to their high cost. Many healthcare systems, particularly in developing regions, face difficulties in integrating these services due to limited funding and the absence of reimbursement policies. Consequently, access to precision genomic testing remains restricted, limiting its broader adoption among patients who could benefit from early diagnosis and personalized treatment.

Key Market Players

• Danaher Corporation
• Merck KGaA
• Revvity, Inc.
• Maravai LifeSciences
• GenScript Biotech
• QIAGEN N.V.
• PacBio Biosciences Inc.
• Oxford Nanopore Technologies plc.
• Illumina, Inc.
• 10x Genomics, Inc.

Report Scope

This report segments the Global Precision Genomic Testing Market as follows, detailing the industry trends:

Market by Technology:

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Microarray Technology
• Sanger Sequencing
• CRISPR/Cas Systems
• Others

Market by Product & Service:

• Consumables
• Equipment
• Services

Market by Application:

• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Reproductive Health
• Rare Diseases
• Others

Market by End Use:

• Hospitals and Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Others

Market by Region:

• North America (United States, Canada, Mexico)
• Europe (France, United Kingdom, Italy, Germany, Spain)
• Asia Pacific (China, India, Japan, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

Company Profiles: A detailed analysis of the major players in the Global Precision Genomic Testing Market.

Available Customizations:

TechSci Research offers customization options for the Global Precision Genomic Testing Market report, tailored to meet a company's specific needs.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Precision Genomic Testing Market

5. Global Precision Genomic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Sanger Sequencing, CRISPR/Cas Systems, Others)
  • 5.2.2. By Product & Services (Consumables (Kits & Reagents), Equipment, Services)
  • 5.2.3. By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Rare Diseases, Others)
  • 5.2.4. By End-Use Hospitals and Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Precision Genomic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product & Services
  • 6.2.3. By Application
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Precision Genomic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product & Services
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End Use
  • 6.3.2. Mexico Precision Genomic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product & Services
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End Use
  • 6.3.3. Canada Precision Genomic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product & Services
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End Use

7. Europe Precision Genomic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product & Services
  • 7.2.3. By Application
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Precision Genomic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product & Services
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End Use
  • 7.3.2. Germany Precision Genomic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product & Services
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Precision Genomic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product & Services
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Precision Genomic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product & Services
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Precision Genomic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product & Services
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End Use

8. Asia Pacific Precision Genomic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product & Services
  • 8.2.3. By Application
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Precision Genomic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product & Services
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Precision Genomic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product & Services
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End Use
  • 8.3.3. South Korea Precision Genomic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product & Services
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End Use
  • 8.3.4. Japan Precision Genomic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product & Services
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Precision Genomic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product & Services
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End Use

9. South America Precision Genomic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product & Services
  • 9.2.3. By Application
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Precision Genomic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product & Services
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End Use
  • 9.3.2. Argentina Precision Genomic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product & Services
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End Use
  • 9.3.3. Colombia Precision Genomic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product & Services
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End Use

10. Middle East and Africa Precision Genomic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product & Services
  • 10.2.3. By Application
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Precision Genomic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product & Services
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End Use
  • 10.3.2. Saudi Arabia Precision Genomic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product & Services
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End Use
  • 10.3.3. UAE Precision Genomic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product & Services
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Precision Genomic Testing Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Danaher Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Revvity, Inc.
• 15.4. Maravai LifeSciences Holdings Inc.
• 15.5. GenScript Biotech
• 15.6. QIAGEN N.V.
• 15.7. PacBio Biosciences Inc.
• 15.8. Oxford Nanopore Technologies plc.
• 15.9. Illumina, Inc.
• 15.10. 10x Genomics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer